diffuse large B-cell lymphoma
Conditions
Interventions
Gold Standard:Pathological diagnosis and genetic test results
Index test:MYC rearrangement, MYD88 mutation, LymphPlex algorithm classification results
Sponsors
Ruijin Hospital, Shanghai Jiao Tong University School of Medicine
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: Patients with diffuse large B-cell lymphoma who underwent ultrasonography with ultrasound-guided core needle biopsy of lymph nodes at Ruijin Hospital from June 2022 to December 2028
Exclusion criteria
Exclusion criteria: 1. Pathologic diagnosis is unclear or complicated with other disturbing pathologic backgrounds, such as concurrent indolent lymphoma or transformed indolent lymphomas; 2. Specialized types of DLBCL: DLBCL originating in the central nervous system, mediastinum, stomach, the testes, or leg DLBCL; 3. Patients with incomplete ultrasound images, clinical data or genetic information;
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Multi-modal ultrasound images and radiomic features; | — |
Secondary
| Measure | Time frame |
|---|---|
| lactate dehydrogenase;PET-CT report;immunohistochemistry;gene test results; | — |
Countries
China
Contacts
Public ContactRonghui Wang
Ruijin Hospital, Shanghai Jiao Tong University School of Medicine
Outcome results
None listed